Journal Article

Add-on Fluvoxamine Improves Primary Negative Symptoms: Evidence for Specificity From Response Analysis of Individual Symptoms

Henry Silver, Nelson Aharon and Alla Kaplan

in Schizophrenia Bulletin

Published on behalf of Maryland Psychiatric Research Center

Volume 29, issue 3, pages 541-546
Published in print January 2003 | ISSN: 0586-7614
Published online January 2003 | e-ISSN: 1745-1701 | DOI: http://dx.doi.org/10.1093/oxfordjournals.schbul.a007026
Add-on Fluvoxamine Improves Primary Negative Symptoms: Evidence for Specificity From Response Analysis of Individual Symptoms

More Like This

Show all results sharing this subject:

  • Child and Adolescent Psychiatry

GO

Show Summary Details

Preview

Establishing that treatment for negative symptoms improves primary features of schizophrenia rather than similar symptoms of other etiology is an important clinical issue. Primary negative symptoms may also differ among themselves in the propensity to respond to a given treatment. In this study, we examined the response of negative symptoms to add-on fluvoxamine by analyzing discrete symptoms independently and controlling for potential confounding variables. Data from two published controlled studies comparing fluvoxamine to placebo were pooled for the analysis. Eleven of sixteen Scale for the Assessment of Negative Symptoms items tested, including key negative symptoms such as affective flattening and alogia, improved. The improvement was not related to base line levels of depressive, extrapyramidal, and positive symptoms or to changes in the symptom scores during the study. The findings support the view that fluvoxamine augmentation can improve primary negative symptoms in chronic schizophrenia patients.

Keywords: Side effects; SSRI; fluvoxamine; negative symptoms; response analysis; schizophrenia; augmentation treatment

Journal Article.  0 words. 

Subjects: Child and Adolescent Psychiatry

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.